News
Tomorrows, a global health technology company that connects patients and physicians with pre-approval treatments, today published a new data report, entitled Searching for solutions: How physicians ...
In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...
54m
News-Medical.Net on MSNAI-guided patient stratification boosts Alzheimer’s trial outcomes and efficiencyScientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.
In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, shares how the company is driving more inclusive enrollment by engaging diverse communities, developing culturally ...
Tony Newberne is a high-risk multiple myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several ...
1h
News-Medical.Net on MSNStudy casts doubt on a widely used shortcut in rectal cancer drug trialsA new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...
A multisite research team has issued ethical and policy recommendations for first-in-human clinical trials involving the transplantation of pig kidneys into humans. The first trial has been approved ...
Scientists have used AI to re-analyse a clinical trial for an Alzheimer's medicine, and identified a group of patients who responded to treatment. The ...
3d
Clinical Trials Arena on MSNAdapting to funding and operational hurdles in today’s clinical trials landscapeUK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.
Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...
Allison Gardner MP dedicated her support for the Rare Cancers Bill to her mother, who died of pancreatic cancer.
A separate analysis of the real-world trial found that those who switched from daily antiretroviral treatment to Cabenuva had fewer concerns about treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results